Are you Dr. Nejadnik?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 27 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1295 Ustilago Dr
San Ramon, CA 94582Phone+1 925-234-0313
Summary
- Dr. Bijan Nejadnik, MD is a gastroenterologist in San Ramon, California. He is currently licensed to practice medicine in California and Colorado.
Education & Training
- Johns Hopkins UniversityFellowship, Gastroenterology, 2002 - 2005
- Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1994 - 1996
- Cook County Health and Hospitals SystemInternship, Internal Medicine, 1993 - 1994
- University Cath De LouvainClass of 1991
Certifications & Licensure
- CA State Medical License 1998 - 2026
- CO State Medical License 2008 - 2019
Publications & Presentations
PubMed
- Mesenchymal Stem Cells Promote an Increase in Neuronal Oscillation via Glutamate Tonic Release.Ricardo L Azevedo-Pereira, Irina Aizman, Bijan Nejadnik
Neuroscience. 2024-08-06 - 1 citationsDetermining the Minimally Clinically Important Difference for the Disability Rating Scale in Persons With Chronic Traumatic Brain Injury.Flora M Hammond, Jessica M Ketchum, Vipul Vinod Patni, Bijan Nejadnik, Damien Bates
Neurotrauma Reports. 2023-01-01 - 3 citationsCell therapies for acute and chronic traumatic brain injury.Masahito Kawabori, Dai Chida, Bijan Nejadnik, Anthony H Stonehouse, David O Okonkwo
Current Medical Research and Opinion. 2022-12-01
Press Mentions
- SanBio Announces Publication Comparing Outcome Measures for Persons with Chronic Traumatic Brain Injury in Expert Review of NeurotherapeuticsNovember 1st, 2021
- Bijan Nejadnik, M.D., Appointed as Chief Medical Officer of SanBioMay 15th, 2019
- Galena Biopharma Presents Positive Interim Safety Data on the NeuVax™ (Nelipepimut-S) Clinical Trial in Combination with Trastuzumab in High-Risk HER2 3+ Patients at the AACR Annual Meeting 2017April 4th, 2017
- Join now to see all